Slabý O - Search Results

1

[New knowledge of the pathogenesis of Crohn's disease].

Ambrůzová B, Rédová M, Michálek J, Sachlová M, Slabý O. Ambrůzová B, et al. Among authors: slaby o. Vnitr Lek. 2012 Apr;58(4):291-8. Vnitr Lek. 2012. PMID: 22559803 Review. Czech.

2

Significant overexpression of Hsp110 gene during colorectal cancer progression.

Slaby O, Sobkova K, Svoboda M, Garajova I, Fabian P, Hrstka R, Nenutil R, Sachlova M, Kocakova I, Michalek J, Smerdova T, Knoflickova D, Vyzula R. Slaby O, et al. Oncol Rep. 2009 May;21(5):1235-41. doi: 10.3892/or_00000346. Oncol Rep. 2009. PMID: 19360299

3

MicroRNA involvement in glioblastoma pathogenesis.

Novakova J, Slaby O, Vyzula R, Michalek J. Novakova J, et al. Among authors: slaby o. Biochem Biophys Res Commun. 2009 Aug 14;386(1):1-5. doi: 10.1016/j.bbrc.2009.06.034. Epub 2009 Jun 11. Biochem Biophys Res Commun. 2009. PMID: 19523920 Review.

4

[DNA and microRNA microarray technologies in diagnostics and prediction for patients with renal cell carcinoma].

Slabý O, Svoboda M, Michálek J, Vyzula R. Slabý O, et al. Klin Onkol. 2009;22(5):202-9. Klin Onkol. 2009. PMID: 19886357 Review. Czech.

5

MicroRNAs in colorectal cancer: translation of molecular biology into clinical application.

Slaby O, Svoboda M, Michalek J, Vyzula R. Slaby O, et al. Mol Cancer. 2009 Nov 14;8:102. doi: 10.1186/1476-4598-8-102. Mol Cancer. 2009. PMID: 19912656 Free PMC article. Review.

6

Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy.

Hanak L, Slaby O, Lauerova L, Kren L, Nenutil R, Michalek J. Hanak L, et al. Among authors: slaby o. Med Sci Monit. 2009 Dec;15(12):CR638-43. Med Sci Monit. 2009. PMID: 19946235

7

microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients.

Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Raja KR, Hodek J, Ovesna J, Michalek J. Hezova R, et al. Among authors: slaby o. Cell Immunol. 2010;260(2):70-4. doi: 10.1016/j.cellimm.2009.10.012. Cell Immunol. 2010. PMID: 19954774

8

Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma.

Michalek J, Ocadlikova D, Matejkova E, Foltankova V, Dudová S, Slaby O, Horvath R, Pour L, Hajek R. Michalek J, et al. Among authors: slaby o. Br J Haematol. 2010 Mar;148(6):859-67. doi: 10.1111/j.1365-2141.2009.08034.x. Epub 2010 Jan 13. Br J Haematol. 2010. PMID: 20067568 Free article.

9

Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?

Kren L, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T, Fadrus P, Smrcka M, Slaby O, Lakomy R, Vanhara P, Krenova Z, Michalek J. Kren L, et al. Among authors: slaby o. J Neuroimmunol. 2010 Mar 30;220(1-2):131-5. doi: 10.1016/j.jneuroim.2010.01.014. Epub 2010 Feb 18. J Neuroimmunol. 2010. PMID: 20167379

10

MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.

Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, Smrcka M, Svoboda M, Dolezalova H, Novakova J, Valik D, Vyzula R, Michalek J. Slaby O, et al. Neoplasma. 2010;57(3):264-9. doi: 10.4149/neo_2010_03_264. Neoplasma. 2010. PMID: 20353279

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page